Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02999269 · ClinicalTrials.gov registry record · Phase 4
ECT Pulse Amplitude and Medial Temporal Lobe Engagement
A Phase 4 study, sponsored by University of New Mexico.
- Completed
- Registry status
- Phase 4
- Development phase
- 62
- Enrollment target
NCT02999269: Completed Phase 4 study, sponsored by University of New Mexico.
NCT02999269 is a Phase 4 study that has completed, run by University of New Mexico. The registered enrollment target is 62 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02999269, a Phase 4 study, has completed, sponsored by University of New Mexico.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 62 participants
- Enrollment target
Study Summary
Electroconvulsive therapy (ECT) remains the gold-standard treatment for patients with depressive episodes. During a typical four-week ECT series, most depressive episodes will respond to treatment and people will improve their level of functioning (return to work or family). Independent of the antidepressant effect of ECT, many patients experience transient memory impairment. This investigation will examine the impact of one ECT parameter (pulse amplitude or current) on brain changes (structure of connections within the brain) and clinical outcomes. The goal of this investigation is to determine the optimal parameter for an individual patient that will maintain the clinical response (reduce depression severity) and minimize side effects (eliminate memory issues related to treatment).
Primary Outcome
Hamilton Depression Rating Scale - 24 item. Scores range from 0 to 76 (higher scores indicate more depression severity)
Interventions
- DEVICE MECTA Spectrum 5000Q Amplitude
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2016-10 |
| Est. Completion | 2020-03-23 |
| Phase | Phase 4 |
What the finished NCT02999269 record still lists
NCT02999269 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which MECTA Spectrum 5000Q Amplitude is the first listed.
NCT02999269 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02999269 about?
NCT02999269 is a clinical study titled "ECT Pulse Amplitude and Medial Temporal Lobe Engagement". Electroconvulsive therapy (ECT) remains the gold-standard treatment for patients with depressive episodes. During a typical four-week ECT series, most depressive episodes will respond to treatment and people will improve their level of functioning (return to work or family). Independent of the antid...
What is the current status of trial NCT02999269?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 62 participants. The study started on 2016-10. Estimated completion is 2020-03-23.
What interventions are being tested in trial NCT02999269?
The interventions under investigation include: MECTA Spectrum 5000Q Amplitude (DEVICE).
Who is sponsoring clinical trial NCT02999269?
This trial is sponsored by University of New Mexico, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02999269's enrollment target sits among peer trials
62 1110th of 2000 higher than 882 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia